Hinge Health Inc. (NYSE:HNGE – Get Free Report) Director Kristina Leslie sold 1,200 shares of the firm’s stock in a transaction that occurred on Thursday, August 20th. The stock was sold at an average price of $88.23, for a total transaction of $105,876.00. Following the sale, the director directly owned 30,387 shares of the company’s stock, valued at $2,681,045.01. The trade was a 3.80% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.
Hinge Health Stock Up 0.0%
Shares of NYSE HNGE opened at $88.44 on Monday. Hinge Health Inc. has a 52-week low of $30.08 and a 52-week high of $93.13. The stock’s 50 day moving average price is $81.40 and its two-hundred day moving average price is $58.45. The stock has a market capitalization of $7.14 billion, a P/E ratio of 69.09 and a beta of 1.30.
Hinge Health (NYSE:HNGE – Get Free Report) last posted its quarterly earnings results on Tuesday, August 4th. The company reported $0.59 EPS for the quarter, beating the consensus estimate of $0.28 by $0.31. Hinge Health had a net margin of 15.15% and a return on equity of 51.60%. The business had revenue of $212.82 million during the quarter. During the same period last year, the firm posted $0.59 earnings per share. The company’s quarterly revenue was up 53.0% on a year-over-year basis. On average, analysts anticipate that Hinge Health Inc. will post 1.25 EPS for the current year.
Institutional Inflows and Outflows
Wall Street Analyst Weigh In
A number of research firms have commented on HNGE. KeyCorp boosted their price target on shares of Hinge Health from $90.00 to $125.00 and gave the stock an “overweight” rating in a research report on Monday, July 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Hinge Health in a report on Monday, August 3rd. Piper Sandler reaffirmed an “overweight” rating on shares of Hinge Health in a report on Wednesday, June 10th. Citigroup reissued an “outperform” rating on shares of Hinge Health in a research note on Monday, July 27th. Finally, Wall Street Zen downgraded Hinge Health from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $100.57.
Read Our Latest Research Report on HNGE
Hinge Health Company Profile
Hinge Health (NYSE: HNGE) is a digital musculoskeletal (MSK) clinic that provides end-to-end solutions for the prevention and management of musculoskeletal conditions. The company’s platform combines wearable motion sensors, personalized exercise therapy guided by licensed physical therapists, and behavioral health coaching to deliver tailored treatment plans. By integrating technology with evidence-based clinical protocols, Hinge Health aims to reduce pain, improve mobility and decrease reliance on more invasive interventions such as surgery or opioid prescriptions.
Founded in 2015 and headquartered in San Francisco, Hinge Health partners with employers, health plans and other payers to offer its self-directed, app-based programs.
Featured Articles
- Five stocks we like better than Hinge Health
- VIG, VYM, and VYMI: Which Vanguard Dividend ETF Is Right for You?
- 3 Closed-End Funds to Maximize Dividend Payments
- Rocket Lab’s Sell-Off Is Fading—Is It Finally Safe to Buy?
- $27 Billion in Buybacks: 3 Stocks Betting Their Strong Runs Aren’t Over
Receive News & Ratings for Hinge Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hinge Health and related companies with MarketBeat.com's FREE daily email newsletter.
